Patents Assigned to Anges Mg, Inc.
-
Publication number: 20170258895Abstract: The present invention provides a combination preparation for inducing a specific immune response to an antigenic peptide, which contains (I) the antigenic peptide, and (II) an expression vector encoding a chimeric hepatitis B virus core antigen polypeptide, into which the antigenic peptide has been inserted or added, wherein said antigenic peptide is inserted in a region of amino acid residues 74-87 or 130-138 of the hepatitis B virus core antigen polypeptide, or added to the N-terminal or C-terminal of the hepatitis B virus core antigen polypeptide, wherein the antigenic peptide of (I) and the expression vector of (II) are substantially simultaneously administered to a subject.Type: ApplicationFiled: November 20, 2015Publication date: September 14, 2017Applicants: ANGES MG, INC., OSAKA UNIVERSITY, DS PHARMA ANIMAL HEALTH CO., LTD.Inventors: Hironori NAKAGAMI, Ryuichi MORISHITA, Hiroshi KORIYAMA, Hideki TOMIOKA, Kenji NAOHARA
-
Patent number: 9446120Abstract: The present invention provides a therapeutic or improving agent for a lifestyle-related disease, containing an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of the lifestyle-related disease-related factor, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.Type: GrantFiled: April 13, 2012Date of Patent: September 20, 2016Assignees: Osaka University, Anges MG, Inc.Inventors: Ryuichi Morishita, Hironori Nakagami, Hiroshi Koriyama, Futoshi Nakagami, Natsuki Yoshida
-
Publication number: 20160250290Abstract: It is possible to stimulate the angiogenesis of an ischemic site declined by diabetes and to recuperate ischemic disease by administering HGF (hepatocyte growth factor) gene to the diabetic ischemic.Type: ApplicationFiled: September 28, 2015Publication date: September 1, 2016Applicant: AnGes MG, Inc.Inventors: Ryuichi Morishita, Toshio Ogihara
-
Publication number: 20160089429Abstract: An oral preparation for the prophylaxis or treatment of a disease with infection by a pathogen, containing a killed lactic acid bacterium expressing, on the surface, an antigen of the pathogen, or a microparticulated form thereof, which has an average particle size of 2.68-30 ?m. An oral preparation for inducing cellular immunity to a target antigen, containing a killed lactic acid bacterium expressing the target antigen on the surface or a microparticulated form thereof, which has a particle size of 2.68-30 ?m.Type: ApplicationFiled: April 18, 2014Publication date: March 31, 2016Applicants: BIOLEADERS CORPORATION, ANGES MG, INC.Inventors: Eiji NOMURA, Akiko TEMMA, Takahiro NAKAZAWA, Ryuichi MORISHITA, II-Han LEE
-
Patent number: 9186439Abstract: Biocompatible nanoparticles 1 which entrap a bioactive substance and whose surface is positive-charge-modified are electrically adhered to a balloon portion 9 of a catheter main body 5 through a negatively charged resin layer 11, and thus a nanoparticle layer 12 is formed. After the catheter main body 5 is indwell in vivo, the nanoparticles 1 are gradually eluted from the nanoparticle layer 12 and are effectively delivered to cells.Type: GrantFiled: March 12, 2009Date of Patent: November 17, 2015Assignees: AnGes MG, Inc., Medikit Co., Ltd., Hosokawa Micron CorporationInventors: Ryuichi Morishita, Hironori Nakagami, Takashi Miyake, Makoto Mitamura, Hiroaki Nakajima, Hiroaki Matsuda, Nao Suizu, Yoshihumi Kawano, Kunihiko Takagi, Hiroyuki Tsujimoto, Yusuke Tsukada, Kaori Hara, Yohei Bando
-
Publication number: 20150133365Abstract: A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran.Type: ApplicationFiled: January 23, 2015Publication date: May 14, 2015Applicant: ANGES MG, INC.Inventors: Takefumi Gemba, Hideki Tomioka, Nao Tamura, Ryoko Sata, Akito Maeda, Akiko Tenma, Toshihide Kanamori, Yoshimi Saito, Shintaro Komaba, Ryuichi Morishita
-
Patent number: 9012417Abstract: A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-?B decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The at least one decoy may be an oligonucleotide including at least two decoys bonded to each other, the at least two decoys being selected from the group consisting of an NF-?B decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The skin disease may be atopic dermatitis, psoriasis vulgaris, contact dermatitis, keloid, bedsore, ulcerative colitis, or Crohn's disease.Type: GrantFiled: February 6, 2002Date of Patent: April 21, 2015Assignee: Anges MG, Inc.Inventors: Ryuichi Morishita, Motokuni Aoki, Toshio Ogihara, Yasufumi Kaneda, Hiroshige Nakamura
-
Patent number: 8969311Abstract: A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran.Type: GrantFiled: May 25, 2010Date of Patent: March 3, 2015Assignee: AnGes MG, Inc.Inventors: Takefumi Gemba, Hideki Tomioka, Nao Tamura, Ryoko Sata, Akito Maeda, Akiko Tenma, Toshihide Kanamori, Yoshimi Saito, Shintaro Komaba, Ryuichi Morishita
-
Publication number: 20140099335Abstract: The present invention provides a therapeutic or improving agent for a lifestyle-related disease, containing an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of the lifestyle-related disease-related factor, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.Type: ApplicationFiled: April 13, 2012Publication date: April 10, 2014Applicants: ANGES MG, INC., OSAKA UNIVERSITYInventors: Ryuichi Morishita, Hironori Nakagami, Hiroshi Koriyama, Futoshi Nakagami, Natsuki Yoshida
-
Circular dumbbell decoy oligodeoxynucleotides (CDODN) containing DNA bindings sites of transcription
Patent number: 8647820Abstract: The present invention provides a circular dumbbell oligodeoxynucleotide (CDODN) comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of a transcriptional factor. The present invention further provides a pharmaceutical composition comprising said CDODN. The pharmaceutical composition can be used for treating and/or preventing a disease or disorder related to such a transcriptional factor. The present invention also provides a method for treating and/or preventing a disease or disorder related to such a transcriptional factor, comprising administering to the subject a therapeutically effective amount of a CDODN comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of the transcriptional factor.Type: GrantFiled: February 28, 2011Date of Patent: February 11, 2014Assignees: Anges MG, Inc.Inventors: In-Kyu Lee, Ryuichi Morishita -
Patent number: 8470765Abstract: A novel polypeptide, and an antibacterial agent, antifungal agent and/or antiseptic containing as an effective ingredient the polypeptide are disclosed. The polypeptide of this invention has an amino acid sequence shown in SEQ ID NOs:1 to 12 and 13 to 31. This antibacterial agent, antifungal agent and/or antiseptic is useful for the prevention, amelioration or treatment of diseases such as burn, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliterans, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, skin abscess, necrotizing subcutaneous infection, staphylococcal scalded skin syndrome (SSSS), folliculitis, facial furuncle, suppurative hidradenitis, carbuncle, infectious paronychia, erythrasma and severe infection (sepsis).Type: GrantFiled: March 5, 2010Date of Patent: June 25, 2013Assignee: AnGes MG, Inc.Inventors: Takefumi Gemba, Hideki Tomioka, Nao Tamura, Akiko Tenma
-
Publication number: 20120172287Abstract: A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran.Type: ApplicationFiled: May 25, 2010Publication date: July 5, 2012Applicant: ANGES MG, Inc.Inventors: Takefumi Gemba, Hideki Tomioka, Nao Tamura, Ryoko Sata, Akito Maeda, Akiko Tenma, Toshihide Kanamori, Yoshimi Saito, Shintaro Komaba, Ryuichi Morishita
-
Publication number: 20120122766Abstract: Novel polypeptides which have an excellent angiogenesis-inducing activity and an excellent antibacterial activity and medical uses thereof are disclosed. The amino acid sequences of the novel polypeptides are shown in any one of SEQ ID NOs:1 to 6. These polypeptides have angiogenesis-inducing and antibacterial activities. Such polypeptides are useful for the prevention, amelioration or treatment of skin wounds caused by a cut wound, surgical wound, erosion, burn, decubitus, intractable wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease or arteriosclerosis obliteran, and for the prevention, amelioration or treatment of bacterial infection in such skin wounds, and the like.Type: ApplicationFiled: November 27, 2009Publication date: May 17, 2012Applicant: ANGES MG, Inc.Inventors: Takefumi Gemba, Hideki Tomioka, Ryoko Sata, Nao Tamura, Akito Maeda, Toshihide Kanamori, Yoshimi Saito, Shintaro Komaba, Ryuichi Morishita
-
Publication number: 20120052104Abstract: A novel polypeptide, and an antibacterial agent, antifungal agent and/or antiseptic containing as an effective ingredient the polypeptide are disclosed. The polypeptide of this invention has an amino acid sequence shown in SEQ ID NOs:1 to 12 and 13 to 31. This antibacterial agent, antifungal agent and/or antiseptic is useful for the prevention, amelioration or treatment of diseases such as burn, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliterans, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, skin abscess, necrotizing subcutaneous infection, staphylococcal scalded skin syndrome (SSSS), folliculitis, facial furuncle, suppurative hidradenitis, carbuncle, infectious paronychia, erythrasma and severe infection (sepsis).Type: ApplicationFiled: March 5, 2010Publication date: March 1, 2012Applicant: ANGES MG, Inc.Inventors: Takefumi Gemba, Hideki Tomioka, Nao Tamura, Akiko Tenma
-
Patent number: 8067388Abstract: A pharmaceutical composition is provided for treatment and prevention of a disease caused by expression of a gene controlled by NF-?B or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-?B decoy, an ets decoy, or a chimera decoy of NF-?B and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. The pharmaceutically acceptable carrier may be a hydrophilic polymer.Type: GrantFiled: January 7, 2009Date of Patent: November 29, 2011Assignee: AnGes MG, Inc.Inventors: Ryuichi Morishita, Motokuni Aoki, Toshio Ogihara, Tomio Kawasaki
-
Patent number: 8067384Abstract: The present invention provides a prophylactic, ameliorative or therapeutic medicament for vascular restenosis, ischemic disease, allergic disease, inflammatory disease, autoimmune disease, or cancer metastasis, invasion (cancer metastasis/invasion) or cachexia based on the inhibitory action on a plural of transcriptional regulatory factor. A chimera (double) decoy of the present invention has plural transcriptional regulatory factor binding sequences in a single molecule thereof. Thus, it is able to inhibit the activity of plural transcriptional regulatory factors with a single molecule. For example, stenosis of an anastomosed site of an artificial blood vessel is caused by thickening of the vascular intima, and this is mainly caused by activation of cell proliferation by an inflammatory reaction occurring at the anastomosed site.Type: GrantFiled: October 20, 2005Date of Patent: November 29, 2011Assignee: Anges MG, Inc.Inventors: Ryuichi Morishita, Toshio Ogihara, Motokuni Aoki, Takashi Miyake
-
CIRCULAR DUMBBELL DECOY OLIGODEOXYNUCLEOTIDES (CDODN) CONTAINING DNA BINDINGS SITES OF TRANSCRIPTION
Publication number: 20110250261Abstract: The present invention provides a circular dumbbell oligodeoxynucleotide (CDODN) comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of a transcriptional factor. The present invention further provides a pharmaceutical composition comprising said CDODN. The pharmaceutical composition can be used for treating and/or preventing a disease or disorder related to such a transcriptional factor. The present invention also provides a method for treating and/or preventing a disease or disorder related to such a transcriptional factor, comprising administering to the subject a therapeutically effective amount of a CDODN comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of the transcriptional factor.Type: ApplicationFiled: February 28, 2011Publication date: October 13, 2011Applicants: ANGES, MG, INC.Inventors: In-Kyu Lee, Ryuichi Morishita -
Patent number: 7994151Abstract: The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets 1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an anType: GrantFiled: May 4, 2009Date of Patent: August 9, 2011Assignee: Anges MG, Inc.Inventors: Ryuichi Morishita, Hiromi Koike, Tadashi Tanabe, Motokuni Aoki
-
Publication number: 20110160132Abstract: Described herein is the discovery that HGFs activate the growth and migration of lymphatic endothelial cells and thereby promote lymphangiogenesis. The present invention is based on this finding, and provides lymphangiogenesis-promoting agents comprising as active ingredients HGFs, or proteins or compounds functionally equivalent thereto. Based on the finding described above, the present invention also provides methods for promoting lymphangiogenesis which comprise the step of locally administering HGFs or proteins functionally equivalent thereto to affected areas in patients with lymphedema.Type: ApplicationFiled: July 28, 2006Publication date: June 30, 2011Applicants: AnGes MG, Inc., Osaka UniversityInventors: Ryuichi Morishita, Yasufumi Kaneda, Hironori Nakagami, Yukihiro Saito
-
Patent number: 7939504Abstract: The present invention relates to a therapeutic preventive agent that includes an angiogenic factor gene (such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), fibroblast growth f actor (FGF), and hypoxia inducible factor (HIF)) as its active ingredient, and the administration of such an agent into the targeted skin diseases-affected area.Type: GrantFiled: June 14, 2007Date of Patent: May 10, 2011Assignee: AnGes MG, Inc.Inventors: Ryuichi Morishita, Kuniaki Nakanishi, Yasufumi Kaneda, Hitoshi Kotani